RxDoctor Payments Data

Christina Baldiga

Psychiatric/Mental Health · Derry, NHNPI 1427306877

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 49.8% of the total.

$1,814in general payments, 2019–2025

Across 125 payments — averaging $14.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$903
  • Sunovion Pharmaceuticals Inc.$236
  • Lundbeck LLC$121
  • Teva Pharmaceuticals USA, Inc.$99
  • Johnson & Johnson$90
  • E.r. Squibb & Sons, L.L.C.$77
  • plus $287 from 8 others

What the payments were for

  • Food & beverage$1,814100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,814 in reported general payments places this provider in the 80th percentile of 264 psychiatric/mental health providers in New Hampshire.

See all psychiatric/mental health providers in New Hampshire

Medicare billing

Part B allowed, 2024
$58,144
Medicare patients
79
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl51$79,360
Aripiprazole201$7,696
VyvanseLisdexamfetamine Dimesylate17$7,292
Methylphenidate ErMethylphenidate Hcl66$7,063
Lisdexamfetamine Dimesylate27$6,098
Lurasidone Hcl20$5,995
Escitalopram Oxalate208$4,006
Quetiapine Fumarate ErQuetiapine Fumarate62$3,290
Methylphenidate Er (La)Methylphenidate Hcl32$2,393
Olanzapine OdtOlanzapine43$2,351
Olanzapine56$1,910
Buspirone Hcl208$1,829
Oxcarbazepine39$1,634
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine45$1,457
Quetiapine Fumarate64$1,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$903$79,36051 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$54$7,29217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 264 psychiatric/mental health providers in New Hampshire.

Other psychiatric/mental health in Derry

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →